English

Interim Report 1 (2018-05-01 – 2018-07-31)

Report this content

Rights issue enables market expansion

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.

In short

  • Net sales for the first quarter increased by 30 % to 856 (660) TSEK.
  • Gross margin amounted to 68 (72) %.
  • During the quarter the company raised 46.3 MSEK before expenses. The rights issue was, however, not fully completed until after the reporting period, resulting in that the rights issue will first be reported in Interim Report 2.
  • The remaining options associated with the two board member and advisor option programs were fully redeemed during the quarter. After option redemption and the rights issue, the number of shares in the company amounts to 13 746 634.
  • After being tested and well received by selected customers, the new software framework HoloMonitor® App Suite was released for customer delivery in July as planned.
  • The Board recently approved the company's most ambitious market expansion to date.

For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.se

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

Subscribe

Documents & Links